Skip to main content
. Author manuscript; available in PMC: 2021 Jul 30.
Published in final edited form as: Anticancer Res. 2017 Jun;37(6):2831–2838. doi: 10.21873/anticanres.11634

Figure 2.

Figure 2.

Mitogen-activated protein kinase kinase 162 (MEK162) and trifluridine demonstrate enhanced antitumor activity in human colorectal cancer cell lines. Dose–survival curves by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for trifluridine, MEK162, and trifluridine combined with MEK162 in KRAS-mutated LS 174T (A), DLD-1 (C), HCT116 (E), SW480 (G), and BRAF-mutated HT-29 (D) human colorectal carcinoma cell lines. Wild-type KRAS/BRAF cell lines included KM12 (B), COLO 320HSR (F), CaCO2 (H), and SNU-C1 (I). X-Axis represents drug concentrations (μM) of trifluridine, MEK162 (in parentheses). Incubation period of 72 hours for all experiments.